Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful ...
Medscape1d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Medscape3y
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. Research Design and Methods Eight subjects completed a three-part double ...
Vivani Medical announces 1st GLP-1 implant in Liberate-1 clinical trial
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
pharmaphorum9d
AstraZeneca improves diabetes pen to maintain its market share
which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
Hosted on MSN1mon
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the ... Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon. "AstraZeneca’s diabetes drug fails ...